Optimizing MRD Identification in B-ALL Using CD123 as a Discriminator of Hematogones and B-Lymphoblasts | ||
| Egyptian Journal of Chemistry | ||
| Articles in Press, Accepted Manuscript, Available Online from 04 August 2025 | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ejchem.2025.390059.11835 | ||
| Authors | ||
| Mohamed S. Shouman* 1; Hadia A. Heikal1; Mohamed Tarif Mohamed2; Fouad Mohamed Fouad2; Mohamed F. Elshal1 | ||
| 1Molecular Biology Department, Genetic Engineering and Biotechnology Institute, University of Sadat City , Sadat City , Egypt | ||
| 2Clinical Pathology Department, Faculty of Medicine, Ain Shams University, Egypt. | ||
| Abstract | ||
| Minimal Residual Disease (MRD) refers to the small number of cancer cells that may remain in the body after treatment, serving as a key indicator of relapse risk and guiding treatment decisions. Detecting MRD using flow cytometry can be challenging because normal B-cell precursors (hematogones) and cancerous B-lymphoblasts share similar physical and biological traits, making them hard to distinguish. This study investigated whether the CD123 marker could improve MRD detection and better differentiate hematogones from B-lymphoblasts in B-acute lymphoblastic leukemia (B-ALL). We used a single-tube flow cytometry approach with anti-human monoclonal antibodies targeting CD19, CD20, CD10, CD34, CD123, and CD45. Our findings showed that CD123 significantly improved the ability to distinguish hematogones from residual B-lymphoblasts. CD123 was strongly expressed on residual B-ALL cells, indicated by a high mean fluorescence intensity (MFI), while it showed moderate expression on mature hematogones, and no expression on less mature hematogones or mature B cells. These results demonstrate clearly that analyzing CD123 expression enhances the accuracy of MRD detection in B-ALL patients. | ||
| Keywords | ||
| Acute lymphoblastic leukemia; Minimal residual disease; MRD techniques; CD123; MRD; B-ALL; Flow cytometry | ||
|
Statistics Article View: 283 |
||
